On July 17, 2024, Cartesian Therapeutics, Inc. closed the transaction. The transaction included participation from 22 investors pursuant to Regulation D. The company has paid sales commission of $4,969,980 in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.42 USD | +2.33% |
|
+8.87% | -10.94% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.94% | 33Cr | |
+20.03% | 13TCr | |
+23.61% | 12TCr | |
+22.56% | 2.75TCr | |
-18.07% | 2.09TCr | |
-14.06% | 1.7TCr | |
-14.81% | 1.63TCr | |
+9.78% | 1.46TCr | |
-46.10% | 1.51TCr | |
+52.34% | 1.39TCr |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Cartesian Therapeutics, Inc. announced that it has received $130.023 million in funding from a group of investors